1. Elanco's 2024 Impact Report emphasizes community-focused animal care initiatives. 2. Innovations contributed $461 million, exceeding revenue targets for 2024. 3. New products enhance pet owner access to parasite protection. 4. FDA approved Bovaer®, aiding sustainability in livestock industry. 5. Employee engagement rises to 71%, reflecting improved corporate culture.
Elanco's exceeding revenue targets and innovative products suggest strong market demand, potentially boosting stock prices, similar to previous product launches like Credelio.
The report highlights growth potential and strong corporate responsibility, likely attracting investors focused on sustainability and innovation.
Sustained growth from innovative products like Bovaer® and improved internal culture will likely realize benefits over the long term.
GREENFIELD, Ind., June 26, 2025 /PRNewswire/ -- Today, Elanco Animal Health Incorporated (NYSE: ELAN) announced the release of its 2024 Impact Report, showcasing its efforts to enhance animal care, not just improving the lives of animals but also the people who care for them. Reflecting on its purpose and strategic alignment, the report introduces a new framework centered on four key communities of impact, celebrating Elanco's culture of 'Going Beyond' for animals, customers, society, and our people.
In launching a new approach to impact reporting, Elanco reaffirms its dedication to delivering lasting positive change. The report outlines eight core ambitions that shape Elanco's business and aim to generate a meaningful impact within the communities we serve worldwide.
"Elanco is dedicated to delivering positive impact through the work we do every day, bringing innovative solutions to veterinarians, farmers, and pet owners," said Jeff Simmons, President & CEO of Elanco. "We're proud to announce a new framework that further embeds our purpose within our business operations, driving growth, accountability, and lasting positive change for society. We celebrate the progress made for these communities of impact and remain committed to advancing our objectives while delivering meaningful value to all our stakeholders."
Elanco invites all stakeholders to explore the full 2024 Impact Report and looks forward to further advancing our purpose of Making Life Better for animals, customers, society, and our people in everything we do.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.
Investor Contact: Tiffany Kanaga (765) 740-0314 or email@example.com
Media Contact: Colleen Parr Dekker (317) 989-7011 or email@example.com
SOURCE Elanco Animal Health